Outbreak

Internal medicine

Endocrinology

Dipeptidyl peptidase-4

Virology

Intensive care medicine

Enzyme

Vildagliptin

Type 2 diabetes

Dipeptidyl peptidase-4 inhibitor

Disease

Dipeptidyl peptidase

Type 2 Diabetes Mellitus

2019-20 coronavirus outbreak

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Biochemistry

Diabetes mellitus

Medicine

Biology

Meta-analysis

Pharmacology

Therapeutic Advances in Endocrinology and Metabolism

Few observational studies have shown a beneficial effect of dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with coronavirus disease 2019 (COVID-19), although results are not consistent. The present systematic review and meta-analysis was undertaken to provide a precise summary of the effect of DPP4i use (preadmission or in-hospital) and mortality in COVID-19 patients with diabetes mellitus (DM).

Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis